loading animation

— Clinical

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

On December 11, 2020, the U.S. Food and Drug Administration (FDA) gave emergency use authorization (EUA) to the Pfizer-BioNTech COVID-19 vaccine. Seven days later, it granted EUA to the Moderna vaccine. On February 27, 2021, an EUA was given to the Janssen/Johnson & Johnson vaccine. At this writing, clinical trials data for a fourth major vaccine — AstraZeneca — had not yet been submitted for FDA review.

One year earlier, none of these vaccines existed; all were the product of intense, accelerated development that included international clinical trials involving hundreds of thousands of participants and expedited review. In three of the four trials — Moderna, Janssen/Johnson & Johnson and Astra-Zeneca — UC San Diego Health and local residents played roles.

“It’s not really surprising,” said Gary Firestein, MD, Distinguished Professor of Medicine and director of the Altman Clinical and Translational Research Institute (ACTRI). “UC San Diego is an international research hub where thousands of clinical trials are conceived or conducted every year, for almost every human condition imaginable.

“The ability to combine a deep bench of experienced investigators with all of the necessary tools and resources makes UC San Diego a natural, go-to destination for clinical trials, and that means San Diegans often get first access to the latest advances in medical science.”

Gary Firestein, MD
Trial By Dire

Gary Firestein, MD (left) is Distinguished Professor of Medicine and director of the Altman Clinical and Translational Research Institute, with project scientist Deepa Hammaker, PhD.

“The ability to combine a deep bench of experienced investigators with all of the necessary tools and resources makes UC San Diego a natural, go-to destination for clinical trials, and that means San Diegans often get first access to the latest advances in medical science.”

And notably, Firestein added, ACTRI investigators were “extremely successful” in recruiting trial participants from underserved and underrepresented communities, a critical element in developing therapeutics that are reflective and effective across all demographics. In the Moderna study, for example, approximately 80 percent of participants in the second (and last) month of recruitment were Hispanic/Latinx.

The Pfizer and Moderna vaccines are based on messenger RNA (mRNA) technology. These vaccines provide cells with instructions to produce a harmless piece of the virus’ characteristic spike protein. The human immune system recognizes the spike protein as “foreign” and builds an immune response against it. Later, if vaccinated persons are exposed to the SARS-CoV-2 virus, their immune systems are already prepared to help prevent infection and illness.

The Astra-Zeneca and Janssen vaccines employ an older approach: An inactivated common cold virus is modified to carry SARS-CoV-2’s spike protein, which the virus uses to enter host cells, spurring the immune system to create neutralizing antibodies that essentially render subsequent exposures to the coronavirus as non-infectious.

Astra-Zeneca and Janssen are built on much-documented vaccine platforms that had worked well with other diseases, including HIV, Ebola and malaria, said Susan Little, MD, professor of medicine at UC San Diego School of Medicine and principal investigator for both UC San Diego trials.

MRNA vaccines are easier and faster to develop, but until the pandemic, the approach had never been approved for human use. “The world was facing an unprecedented crisis; millions infected, hundreds of thousands of people already dead,” said Stephen Spector, MD, Distinguished Professor of Pediatrics and principal investigator in San Diego for the Moderna trial. “A vaccine was desperately needed, as soon as possible.”

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

All of the trials, both in San Diego and around the world, were accelerated efforts, conducted over the course of months, not the usual five to 10 years. That alacrity demanded spending billions of dollars and making some educated guesses.

For example, drug manufacturers said injections of the two-dose Pfizer and Moderna vaccines should be given 21 and 28 days apart, respectively, but those intervals were set, in part, to hasten data collection and speed review. Eventually, the Centers for Disease Control said dose intervals could be up to 42 days apart with no negative consequences, and longer intervals may actually produce a more robust immune response.

Initial clinical trial data indicated all of the EUA-granted vaccines were strongly effective against SARS-CoV-2. Concerns grew, however, that the vaccines were less effective against new virus variants emerging around the world, from the United Kingdom and South Africa to Brazil and India. Subsequent data suggests the vaccines remain effective, both preventing infection and dramatically reducing the risk of severe disease and hospitalization.

Davey Smith, MD, is a translational research virologist and head of Infectious Diseases and Global Public Health at UC San Diego School of Medicine. He works in both vaccine development and in studying viral variants.

“It’s the nature of SARS-CoV-2, like all viruses, to evolve, to adapt to any challenges that might threaten survival. COVID-19 vaccines will need to be modified and improved going forward. Every year, the flu shot is a different formulation. Something similar might be necessary with SARS-CoV-2 and future variants to keep the virus under control.”

Much effort now focuses on refining current vaccines, creating new options and developing boosters. One question still to be fully resolved is how long do current vaccines remain effective. One clinical trial involving UC San Diego will try to provide answers, comparing transmission and infection rates between two groups of students, one vaccinated, the other not.

Other clinical
trials

Vaccines were not the only target of COVID-19 trials at UC San Diego Health. More than two dozen have been launched, many assessing new or repurposed drugs and therapies.

For example, UC San Diego Health researchers have been involved in clinical trials assessing the antiviral drug remdesivir and the repurposed drugs tocilizumab, used to treat arthritis and other inflammatory diseases, and ramipril, used to treat hypertension.

They are studying the immune response to SARS-CoV-2 in cancer patients and the likely outcomes of chronic kidney disease patients with COVID-19 infections. And they are evaluating viral transmission risk of persons fully inoculated with the Moderna vaccine and among asymptomatic children.

— Research

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

The first months of the COVID-19 pandemic were marked, contrarily, by both scarcity and abundance. Personal protective equipment, such as masks and face shields, were in short supply. Access to ventilators, critical to keeping patients breathing, was limited. That scarcity evoked an abundance of anxiety and concern. 

While UC San Diego Health supply chain administrators scoured sources, known or new, for more of just about everything (often with remarkable success), students and faculty across campus stepped up to fill in the gaps with imagination and invention. 

In particular, UC San Diego Health physicians and engineers at the Jacobs School of Engineering worked hand in hand to build emergency ventilators and tools to help protect clinicians and patients alike. Many labs with laser cutters and 3D-printers began making face shields. Some of these efforts were suspended once regular supply chains were re-established, but others continue.

For example, James Friend, PhD, a professor in the Department of Mechanical and Aerospace Engineering; Lonnie Petersen, MD, PhD, also in the department and an adjunct professor in radiology at UC San Diego Health; and assistant project scientist Casper Petersen, MD, worked with students to design and build an emergency ventilator that converted a manual ventilator (patient face mask and bag that is squeezed by hand to push air into the patient’s lungs) so that it worked mechanically without constant human operation. The team worked closely with anesthesiologists and respiratory therapists to ensure the device met specifications and requirements. 

The resulting ventilator’s blueprints are available under an open source patent. Manufacturing costs are approximately $500, while state-of-the-art mechanical ventilators cost at least $50,000. Components can be rapidly fabricated and assembled in 15 minutes. Researchers are still gathering data about the device.  “Over the next couple of years we will find new applications for this work,” said Petersen. 

“Over the next couple of years we will find new applications for this work”

Lonnie Petersen, MD, PhD

Friend also collaborated Timothy Morris, MD, a pulmonologist at UC San Diego Health, to develop a vacuum exhausted isolation locker, dubbed VEIL. The device is essentially a large bubble placed over a supine patient’s head and upper body, creating an oxygen-rich environment that also prevents air — and possibly droplets contaminated by the SARS-CoV-2 virus — from leaving the enclosure. The project was supported by the Galvanizing Engineering in Medicine program at UC San Diego, along with seven other projects. The work also received support from the Prototyping Lab at the Qualcomm Institute.

A description of VEIL was published in the Journal Infection Control & Hospital Epidemiology and some of the finished devices were used in clinical practice. A second type of protective box, called Coronavirus Safety during Intubation and Extubation or COSIE, was designed to protect physicians ventilating patients from aerosols and droplets. Field tests for COSIE were published in the Journal of Cardiothoracic and Vascular Anesthesia.

Numerous other projects came to the fore. Among them: Nanoengineers led by Jessie Jokerst, PhD, associate professor, developed a color-changing test strip
that can be applied to face masks to detect SARS-CoV-2 on people’s breath or saliva. The approach is designed for daily COVID-19 surveillance in high-density, indoor settings, such as hospitals, nursing homes, shelters and prisons. 

Ben Smarr, PhD, assistant professor in the Department of Bioengineering, partnered with colleagues at UC San Francisco and Massachusetts Institute of Technology to determine whether data collected by devices worn on the finger can be reliably used to detect the onset of fever, a leading symptom of both COVID-19 and the flu. Early data from a multi-institution research study involving more than 65,000 participants called TemPredict suggests the answer is yes. Research is ongoing. 

Nicole Steinmetz, PhD, professor of nanoengineering; Jon Pokorski, PhD, associate professor of nanoengineering; and colleagues are using plant viruses to develop various technologies related to COVID-19, such as probes for testing and new platforms to create stable vaccines.

UC San Diego scientists, engineers and physicians continue to press ahead on these and other ideas. Some are big and bold, some perhaps less so, like a sensor that can measure temperature and respiration, both key vital signs for monitoring patients with COVID-19 and other conditions. The sensor is tiny, literally as obvious as Lincoln’s nose on a penny.

— Research

Zoo Gorillas Test Positive for Coronavirus

UC San Diego Health physicians assist in treatment

Experts say COVID-19 is a zoonotic disease. The virus that causes it — SARS-CoV-2 — jumped from one species, perhaps a bat, to humans. That assumption continues to be investigated, but one thing is clear: COVID-19 is not strictly a human disease.

Though people are its primary victims, there have been SARS-CoV-2-positive cases reported in domestic cats and dogs, minks, ferrets, cougars, lions, leopards and tigers.

In January 2021, western lowland gorillas at the San Diego Zoo Safari Park were added to the list. It became international news, in part because of what it might portend for all life on Earth.

It’s not known exactly how the gorillas became infected. Best guess: They picked up the virus from an infected, but asymptomatic, wildlife care specialist. Nearly half of the pandemic’s spread can be attributed to asymptomatic infections, says the CDC.

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

Transmission is also easier when species are related. Both humans and gorillas are primates, sharing approximately 98 percent of the same DNA. “The closer you are on the evolutionary tree, the more likely you are to be susceptible to the same disease,” Pascal Gagneux, PhD, associate director of the Center of Academic Research and Training in Anthropogeny at UC San Diego, told The San Diego Union-Tribune.

Two diagnosed gorillas subsequently infected others in the eight-ape troop, but most of the apes experienced only minor symptoms — sneezing, coughing, lethargy and fatigue — and all fully recovered. A 49-year-old silverback named Winston suffered heart issues and pneumonia, but recovered after receiving experimental antibody treatment.

“UC San Diego Health was involved in
consultations with the zoo.”

Jess Mandel, MD

“UC San Diego Health was involved in consultations with the zoo,” said Jess Mandel, MD, chief of the Division of Pulmonary, Critical Care and Sleep Medicine. “We helped review Winston’s chest CT and also advised regarding treating him with monoclonal antibodies and other therapies. It was a unique collaboration that combined UC San Diego Health’s expertise in treating patients with COVID-19 and the zoo’s expertise with nonhuman primates.”

In March, the zoo’s four orangutans and five bonobo chimpanzees were inoculated with an experimental vaccine developed by a veterinary pharmaceutical company.

— Research

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

As researchers expanded investigations into how the SARS-CoV-2 virus spreads, infects and who is most vulnerable, scientists at UC San Diego School of Medicine, in part supported by the Family Larsson-Rosenquist Foundation, focused on a particular aspect: breastfeeding women and breast milk.

In particular, they launched studies to determine whether COVID-19 is transmitted via human milk and whether human milk can protect infants from COVID-19.

To the first question, the answer appears to be no. A study published August 19, 2020 in JAMA analyzed 64 samples of breast milk collected by the Mommy’s Milk Human Milk Research Biorepository from 18 women across the United States infected with SARS-CoV-2. Although one sample tested positive for viral RNA, subsequent tests found that the virus was unable to replicate, and thus unable to cause infection in breastfed infants.

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

“Detection of viral RNA does not equate to infection. It has to grow and multiply in order to be infectious, and we did not find that in any of our samples,” said Christina Chambers, PhD, MPH, co-principal investigator of the study, professor of pediatrics at UC San Diego School of Medicine, director of Mommy’s Milk Human Milk Research Biorepository and co-director of the UC San Diego Center for Better Beginnings. “Our findings suggest breast milk itself is not likely a source of infection for the infant.”

The answer to the second question will take longer. Research is on-going, with study volunteers in the United States and Canada being monitored while breastfeeding and following infection. Scientists will also track infant growth and development via the child’s pediatrician for at least one year following infection.

“We already know breast milk contains properties that help protect infants from diseases, such as diarrhea and pulmonary infections. We want to know whether breast milk components, with their antiviral properties, might actually protect infants from COVID-19,” said Lars Bode, PhD, director of UC San Diego’s Larsson-Rosenquist Foundation Mother-MilkInfant Center of Research Excellence (MOMI CORE).

“We want to know whether breast milk components, with their antiviral properties, might actually protect infants from COVID-19.”
Lars Bode, PhD

— Research

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

For the first few months of the pandemic, SARS-CoV-2 was called simply “the novel coronavirus,” “novel,” meaning scientists hadn’t seen it before. And yet the ability to see — really see, at the atomic level — what a microbe looks like and how it interacts with human cells is crucial in helping researchers design better methods to prevent or disrupt those interactions.

Rommie E. Amaro, PhD, professor in the UC San Diego Department of Chemistry & Biochemistry, and collaborators, were among the first to get a close look. They created models of the virus and its interactions with human cells, based on structural data generated from cryo-electron tomography and cryo-electron microscopy — leading-edge techniques that allow researchers to glimpse molecular structures at unprecedented resolution — and a combination of computer modeling and molecular dynamics simulations.

The models revealed a trove of information. For example, SARS-CoV-2’s infamous spike protein, protrusions that help it grab hold of human cells, is coated in sugar molecules known as glycans. These glycans change the spike protein’s shape — important information for researchers trying to target it with new drugs, or drum up antibodies against it with vaccines.

A

THE VIRUS. The spike proteins protruding from the virus’ spherical lipid bilayer are shown in gray, with glycans highlighted in dark blue.

B

The spike protein. This is the SARS-CoV-2’s spike protein in its open state. The spike protein is shown in cyan and the sugars forming a so-called “glycan shield” are depicted in dark blue. The spike is embedded in the viral membrane, shown at the bottom as multicolored carpeting.

C

The infection. SARS-CoV-2 (top) latches onto the ACE-2 receptor (yellow), a molecule on the surface of human cells that the virus uses like a doorknob to gain entry and establish infection.

A. THE VIRUS
Image credit: Lorenzo Casalino
Modeling credit: Abigail C. Dommer, Lorenzo Casalino
Zied Gaieb, Rommie E. Amaro

B. THE SPIKE PROTEIN
Image credit: Lorenzo Casalino
Modeling credit: Lorenzo Casalino, Zied Gaieb, Rommie E. Amaro

C. THE INFECTION
Image credit: Lorenzo Casalino
Modeling credit: Lorenzo Casalino, Abigail C. Dommer Zied Gaieb, Emilia P. Barros, Rommie E. Amaro

— Clinical

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

For most patients who succumbed to COVID-19, the ultimate cause of death was pneumonia, a condition in which inflammation and fluid buildup make it difficult to breathe. Severe pneumonia often requires lengthy hospital stays in intensive care units and assisted breathing from mechanical ventilators.

To quickly detect pneumonia — sometimes before a COVID-19 diagnosis — UC San Diego Health clinicians used artificial intelligence to augment lung-imaging analysis, part of a clinical research study.

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.
Trial By Dire

Gary Firestein, MD (left) is Distinguished Professor of Medicine and director of the Altman Clinical and Translational Research Institute, with project scientist Deepa Hammaker, PhD.

“Pneumonia can be subtle, especially if it’s not your average bacterial pneumonia. If we could identify those patients early, before you can even detect it with a stethoscope, we might be better positioned to treat those at highest risk for severe disease and death,” said Albert Hsiao, MD, PhD, associate professor of radiology at UC San Diego School of Medicine and a radiologist at UC San Diego Health.

Hsaio’s team developed a machine-learning algorithm that made earlier detection possible.

The images show chest X-rays from a patient with COVID-19 pneumonia. At top is the X-ray with the AI algorithm applied, indicating pneumonia. Below is the original X-ray. This particular patient also happened to have a pacemaker device and an enlarged heart, indicators that, while a subject may have significant underlying health issues, the algorithm was still able to do its job.

— Clinical

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

During the pandemic, Joe Bautista, a registered nurse at the UC San Diego Health COVID-19 Telemedicine Clinic, collected songs from his patients as part of a satirical “Nurse’s Fee,” in which Bautista would ask each patient to tell him which song best described 2020 for them.

As the pandemic spread and deepened in San Diego, Michele Ritter, MD, and other infectious disease specialists launched the COVID-19 Telemedicine Clinic, which was open to anyone in the community with a recent COVID-19 diagnosis. Through video visits and phone calls, nurses and physicians consulted with people who had mild to moderate symptoms.

Every week, Bautista called and checked in on his patients to ensure they were on their way to recovery at home. These song requests helped Bautista build relationships with his patients, which in turn furthered the healing process by providing a personal connection.

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

Now, Bautista’s COVID-19 playlist has more than 500 songs. Popular titles include “I’m a Survivor” by Destiny’s Child, “House Arrest” by Sofi Tukker, and “You Can’t Always Get What You Want” by the Rolling Stones.

— Clinical

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

“You don’t look like the doctor,” the patient’s husband says. “I bet I wouldn’t catch you running around in the street, would I.”

The resident stops short, but isn’t surprised. As a Black man, he has confronted such comments many times. This particular comment is prompted, in part, by the recent death of Ahmaud Arbery, a 25-year-old Black man pursued and fatally shot by white community members while he was jogging through his South Georgia neighborhood on February 23, 2020. At the time, no arrests were made.

The resident feels powerless. He turns to leave the room, believing that no matter how he responds, any reply might jeopardize his career — and wouldn’t change anything.

Three months following the death of Arbery, George Floyd dies after a Minneapolis police officer kneels on his neck for nine minutes and 29 seconds. This time, more than 30 medical students and residents in the School of Medicine speak up, penning a pair of letters to school leadership demanding change.

“We had been meeting with medical students from underrepresented communities in the field of medicine for some time in order to address the need for equity, diversity and inclusion in medicine.”

Steven Garfin MD

“We had been meeting with medical students from underrepresented communities in the field of medicine for some time in order to address the need for equity, diversity and inclusion in medicine,” said Steven Garfin, MD, interim dean, UC San Diego School of Medicine. “But we realized in this situation with our resident, and after receiving the two letters, a more urgent response was necessary to ensure policies and procedures, as well as education and training, were put in place for medical professionals — and patients.”

And so the Anti-Racism Framework for UC San Diego Health Sciences was established, along with multiple work streams tasked with addressing specific issues and demands raised in the letters.

The five main categories of work are organized by Education; Organizational Training and Enrichment; Recruitment, Retention and Representation; Health Care Policies; and Health Disparities. Each group seeks to improve equity, diversity and inclusion efforts where we all learn, work, teach and receive care.

Invitations to join a work group were sent to all faculty, staff, students and residents; nearly 400 individuals expressed their interest in helping.

In Fall 2020, the work groups began meeting regularly to address issues affecting not just residents, nurses and medical professionals, but hospital support staff, such as environmental services and food and nutrition as well.

“First and foremost, we listened, and it was very painful to hear the stories,” said Garfin. “We thought we understood and empathized, but we can’t do this right unless we’re put in the shoes of others. We opened our eyes to what had to be done because we can’t continue to relive centuries of this systemic racism.”

“We thought we understood and empathized, but we can’t do this right unless we’re put in the shoes of others. We opened our eyes to what had to be done because we can’t continue to relive centuries of this systemic racism.”

Steven Garfin MD

Immediate actions included leadership recruitment and new positions, such as a Chief Administrative Officer for Health Equity, Diversity and Inclusion at UC San Diego Health and an Assistant Vice Chancellor for Health Equity, Diversity and Inclusion for UC San Diego Health Sciences.

New clinical policies were created to protect staff and set expectations for patients on what is acceptable behavior while receiving care. “We needed to be clear that we will not tolerate racist behavior at UC San Diego Health. These policies are critical because they affect everyone,” said Thomas Savides, MD, chief experience officer at UC San Diego Health and chair of the Health Care Policies work group.

“Specifically, we’ve created two policies on anti-racism that would promote an inclusive work environment for our staff and also help mitigate racist encounters with patients.” For team members, the policies provide guidance on how to manage racist events involving patients. Each event will be managed by a team to evaluate the situation, escalate for additional action, review the event and track patterns.

For patients, certain expectations, rights and responsibilities are expressly outlined, explaining that racism exhibited by patients, family members or anyone visiting the health system will not be tolerated. The updated policy will be provided to patients upon admission.

“It’s gratifying to know that we’re making changes now that will be in place for decades to come.”

Thomas Savides, MD

“It’s been a coordinated effort instead of a lot of people working in silos,” said Savides. “It’s gratifying to know that we’re making changes now that will be in place for decades to come.”

Systemic racism has been public health crisis for centuries. Numerous high-profile deaths, often involving police, fueled an explosion of outrage and grief in 2020, which soon spread to not only include disproportionate violence, but also health disparities and the impact of COVID-19 on communities of color.

“Our CEO Patty Maysent sent out a call to action for physicians and nurse leaders: Stand up and contribute to ensure patients have more equitable health outcomes,” said Amy Sitapati, MD, chief medical information officer of Population Health at UC San Diego Health and chair of the Health Disparities work group. “We were tasked with finding a way to become a cohesive unit of change and the most important thing we needed to do first was allow for open and transparent conversations.”

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

Sitapati’s work group focused initial efforts on listening to staff who were personally affected by health care inequities, experienced racism in the workplace, and who had witnessed inequities in patients they cared for. Collectively, they were moved by how the pandemic dramatically impacted Latinos in San Diego.

“During the surge, half of my inpatients with COVID-19 only spoke Spanish. We also noticed our Spanish-speaking Latinx population were developing severe cases,” said Sitapati. “Our goal as a work group was to be strategic and personal to ensure we were more inclusive to all patients and staff.”

The work consisted of adapting communications for frontline staff — including nonclinical departments such as food and nutrition and environmental services — to be more linguistically inclusive and at an appropriate literacy level. Translations for staff town halls were provided to ensure staff received leadership updates in the language they best understood.

For patients, the team understood the underlying importance that structural barriers and social determinants were impacting patients at risk for severe COVID-19.

“We were able to load in the social deprivation index for every person, based on their census block provided by the California Healthy Places Index (HPI),” said Sitapati. “Just by knowing where a patient lived, we could determine their HPI and prioritize care for patients with the highest risk.”

Not only did this apply in the clinical setting, but it also assisted the work group in determining where to focus COVID-19 vaccination efforts as UC San Diego Health ramped up its mobile vaccine clinic, which delivers vaccines directly to communities in the greatest need.

Since the Anti-Racism Framework was established, Sitapati has noticed a culture shift at UC San Diego Health that she believes is a result of the collective efforts of all involved.

“The timing of these two extremely emergent events — COVID-19 and the social injustice experienced by persons of color — truly highlighted the severity of health disparities among certain communities and really emphasized the critical need for change,” said Garfin. “Which is why it’s so important for those in medicine to understand how racist sentiments and biases affect a person’s overall health. As educators, this training will become the norm as we mentor the next generation of doctors and work with our current doctors actively providing health care.”

— Clinical

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

“It’s here!” Nancy Yam, PharmD, was chatting with colleagues outside her office at UC San Diego Medical Center in Hillcrest early in the morning of December 15, 2020 when her smart watch pinged with the message they had all been waiting for.

The group darted for the stairs leading to the shipping and receiving area. Yam glanced at another message on her watch. “No, it’s already been taken up!” The giddy group reversed course and a few moments later, they burst through the back door to the hospital’s pharmacy.

There, two cardboard boxes sat on a cart. The boxes might have contained anything, but Yam and her co-workers knew exactly what lay within. They had been waiting for this shipment and this moment for months, along with the entire country. The first COVID-19 vaccines were in the house.

Word spread and within minutes people from neighboring work areas arrived to take pictures of the boxes and to text families and friends.

It was a historic moment, but Yam, associate chief pharmacy officer at UC San Diego Health, and her team could not pause to appreciate its significance. They needed to get work. Carefully following instructions from Pfizer and the Food and Drug Administration (FDA), they moved the vaccine into supercool freezers in the “Freezer Pharm.” They collaborated with team members from Facilities and Emergency Management to coordinate delivery of doses and ancillary items, such as needles, syringes and vaccine cards, to Jacobs Medical Center in La Jolla. They consulted with physicians and nurses to determine how and when the vials would be thawed and reconstituted, and how nurses would administer doses.

On December 16, the following day, doctors, nurses and staff lined the hallway and cheered as the first employees were called in to receive their vaccinations. Within four weeks, more than 10,000 UC San Diego Health employees had been vaccinated, an effort led by Shira Abeles, MD; Marlene Millen, MD; and others.

“Before the vaccines became available, we were working around the clock to prepare for surges of patients with COVID-19, to make sure that we could provide them, as well as our other patients, with outstanding care and to make sure we weren’t going to run short of medications — all with so many unknowns and things changing daily,” Yam said. “ “At the same time, many people were dealing with so much loss, anxiety, weddings delayed and kids out of school.

“That’s why it was so meaningful to be able to play a part in equitable distribution of the vaccine, starting with our own health care heroes. It was a day of pride, and hope.”

“At the same time, many people were dealing with so much loss, anxiety, weddings delayed and kids out of school.”

Nancy Yam, PharmD

Left to right, the Padres’ Friar mascot; Lydia Ikeda, senior director of COVID operations at UC San Diego Health; and Nathan Fletcher, chair of the San Diego County Board of Supervisors, celebrating the 100,000th dose delivered at Petco. More than 225,000 doses would be administered before the site closed.

25,000 community members signed up to volunteer at UC San Diego Health’s vaccination superstations.

California Governor Gavin Newsom tours the Vaccination Super Station at Petco Park with UC San Diego Health CEO Patricia Maysent.

Thousands of UC San Diego and local community members received their COVID-19 vaccination at the Recreation, Intramural and Athletic Complex (RIMAC) superstation on UC San Diego’s La Jolla campus.

Hidden
Figures

From setting up surge tents and testing sites to launching vaccination super stations to establishing that fire and life safety protocols were in place in clinical spaces, the facilities and engineering team helped make it possible for staff to provide the highest level of care for patients during the pandemic. “If our clinical staff can come in to work every day and are able to do their job of taking care of patients in their greatest time of need, then we’re doing our job and it’s an honor,” said Tim Rielly, director of facilities engineering at UC San Diego Health. “We’re always here, working behind the scenes, and our goal is to keep everyone safe.”

Partnering
to expand

A few weeks later, UC San Diego Health CEO Patricia Maysent was on the phone, strategizing with San Diego County and other UC San Diego Health leaders about how best to quickly and safely vaccinate all of the remaining health care workers in the region. “That was a Wednesday, and I asked ‘What would it take to get 5,000 vaccines in arms a day starting Monday?’” Maysent said. “’What would that take? Can you do it?’”

Everyone was eager, but one of the limiting factors was the need for a space large enough to accommodate thousands of people. Maysent thought of the San Diego Padres, with whom she had worked closely for several years. (UC San Diego Health is the Official Health Care Provider of the San Diego Padres, the region’s Major League Baseball team.) Five days later, the state’s first drive-through Vaccination Super Station opened in the Tailgate Lot next to Petco Park, the Padres’ stadium.

“The rapid buildout and staffing of the COVID-19 vaccine hub at Petco Park was a massive undertaking, and it would not have been possible without our partners at the county, city and the Padres,” Maysent said. “We are extremely proud of San Diego for coming together during this crisis, leveraging the innovation and collaboration for which our region is known, to support the health and safety of the entire community.”

“The rapid buildout and staffing of the COVID-19 vaccine hub at Petco Park was a massive undertaking, and it would not have been possible without our partners at the county, city and the Padres”

Patricia Maysent

The massive undertaking, led by Lydia Ikeda, senior director of COVID-19 operations; Will Ford, director of project management; and others, involved 42,000 square feet of tenting, 5,700 feet of power cable, 85 laptop computers on wheels, wireless internet provided by the Padres, and a self-scheduling website integrated with UC San Diego Health’s electronic health record system. The site was run by 300 clinical and administrative staff and volunteers per day. Yam’s pharmacy team and their Storehouse colleagues prepared and delivered the doses and ancillary items daily, and remained on call, ready to drop everything and drive downtown with more doses if the team was able to open up more appointments.

“After all that work, on the first day, when we had the first patient enter the site, the feelings I had were awe, inspiration and hope,” Ikeda said. “It felt like the first step in a long journey, and amazing that we accomplished it in such short order.”

The Vaccination Super Station administered approximately 5,000 vaccines per day, 12 hours per day, seven days a week.

The community’s response to the superstation was overwhelmingly positive, including an outpouring on social media to express gratitude and pride in the San Diego region for being able to rapidly collaborate to scale-up and streamline vaccine distribution at a time when most regions were struggling to implement the basic infrastructure. More than 25,000 people signed up to volunteer.

The site was visited by many elected officials, including California Governor Gavin Newsom and representatives from other health systems. Petco site leaders were asked to present to national organizations and were interviewed frequently by local and national media. Petco even received a shout-out during a White House news conference.

“What I’m probably most proud of is that the Petco site served as a model for other similar mass vaccination centers in the state, and around the country,” Maysent said.

Staff and volunteers were treated to donated meals and treats, visits from Padres alumni, high-fives from the Padres mascot, an impromptu concert from an opera singer during her post-vaccination observation period and thank-you cards from kids grateful that their grandparents had been vaccinated.

The Petco site operated for 68 days, administering more than 225,000 vaccine doses. It permanently closed March 20, 2021 with the advent of the Major League Baseball season. As the County began to open up vaccine eligibility to additional occupations and age groups, UC San Diego opened a second super site at the Recreation, Intramural and Athletic Complex (RIMAC) on the La Jolla campus. The site served UC San Diego employees, students and patients, as well as members of the community. In the almost four months it operated, more than 195,000 doses were administered at the RIMAC site.

“One of the things I’ll never forget is how grateful people were to get their vaccines, how they thanked us for saving their lives, even if they’d been waiting in traffic for hours to get there,” Ikeda said. “It was a privilege to be able to help our community this way, and we, in turn, were buoyed by them. It was exactly what we needed after months of being ‘COVID-weary.’”

“It was a privilege to be able to help our community this way, and we, in turn, were buoyed by them. It was exactly what we needed after months of being ‘COVID-weary.’”

Lydia Ikeda

Moving the needle: Mobile and pop-up clinics were created to boost access to vaccines in hard-hit communities and across the border. 

Other clinical
trials

While the supersites were exceptional at vaccinating huge numbers of people, they often weren’t accessible to those who needed them most. In March 2021, with support from philanthropists John and Sally Hood, UC San Diego Health, led by Abeles, Ikeda and others, began collaborating with trusted community-based organizations to expand outreach and support widespread deployment of vaccines to San Diego County communities affected by the greatest number of COVID-19 cases and highest rates of hospitalizations and deaths. These mobile vaccine clinics were designed to reach more patients more effectively, and help ease barriers, such as lack of transportation to vaccine appointment sites and distrust in health care providers outside of local communities.

One of the first stops was a complex of warehouses and trucking services in Otay Mesa, where a team vaccinated approximately 1,200 people who deliver food and goods throughout San Diego County and the nation. In following weeks and months, the team administered vaccines in churches, high schools and work places.

“No virus, especially one as infectious as COVID-19, recognizes borders,” said Abeles, dubbed the “vaccine czar” in a February 2021 Science article. “As a leading advocate and provider for health care across our region, UC San Diego Health quickly recognized the public health benefit in joining our binational community in expanding outreach and supporting the widespread deployment of COVID-19 vaccines to help end this pandemic.”

In May, UC San Diego Health set up a mobile clinic at the Mexican border in San Ysidro, where a team vaccinated 10,000 maquiladora workers employed by United States subsidiary companies over seven days. The clinic was made possible through the efforts of the Consulate General of Mexico and County of San Diego.

“Our ability to vaccinate a quarter of San Diegans, and save so many lives, it was historic,” Ikeda said. “We’ll be telling these stories to our grandkids the way our grandparents talk about the polio vaccine.”

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

Vaccines by the Numbers*

— Research

Trials By Dire

UC San Diego Health was part of three of the first four clinical trials resulting in approved COVID-19 vaccines, and has conducted more than two dozen other investigations of potential drugs and therapies

A molecule known as ACE2 sits like a doorknob on the outer surfaces of cells that line the lungs’ passageways. Since early 2020, researchers have known that SARS-CoV-2 primarily uses the ACE2 doorknob to enter these cells and establish a COVID-19 respiratory infection. Finding a way to lock out that interaction as a means to treat infection has become the goal of many research studies.

To speed up the search, many researchers have turned to testing repurposed drugs — medicines already known to be safe for human use because they are FDA-approved for other conditions.

Before it became infamous for its role in COVID-19 infections, ACE2 was known to regulate blood pressure. And since prescription statins — widely used cholesterol-lowering drugs — can affect ACE2, UC San Diego Health researchers analyzed the electronic medical records of 170 statin-taking patients with COVID-19 to see what effect the medications had on virus vulnerability.

They found that statin use prior to hospital admission for COVID-19 was associated with a more than 50 percent reduction in risk of developing severe COVID-19, compared to those with COVID-19 but who were not taking statins. Patients with COVID-19 who were taking statins prior to hospitalization also recovered faster. The study, led by Lori Daniels, MD, professor and director of the Cardiovascular Intensive Care Unit at UC San Diego Health, and Karen Messer, PhD, professor and chief of the Division of Biostatics and Bioinformatics, was published in the American Journal of Cardiology.

Another UC San Diego School of Medicine team discovered that SARS-CoV-2 can’t grab onto ACE2 without a carbohydrate called heparan sulfate, also found on lung cell surfaces, where it acts as a co-receptor for viral entry. “ACE2 is only part of the story,” said Jeffrey Esko, PhD, Distinguished Professor of Cellular and Molecular Medicine at UC San Diego School of Medicine and co-director of the Glycobiology Research and Training Center. “It isn’t the whole picture.”

“The world was facing an unprecedented crisis, millions infected, hundreds of thousands of people already dead.”

Stephen Spector, MD.

Esko’s team discovered that heparin — an FDA-approved form of heparan sulfate widely used to prevent and treat blood clots — reduces the ability of SARS-CoV-2 to infect human cells cultured in the lab by up to 90 percent. Essentially, the heparin acts as bait to lure and bind the coronavirus, keeping it away from human cells. The study was published in Cell.

Elsewhere, UC San Diego physician-scientists like Constance Benson, MD, professor of medicine, and Dan Sweeney, MD, helped conduct clinical trials of remdesivir, an antiviral originally designed to treat Ebola and Marburg infections, and the first repurposed drug approved by the FDA for treating COVID-19. It was found to shorten hospital stays and recovery time.

Not every repurposed drug is a success story. Atul Malhotra, MD, research chief of pulmonary, critical care and sleep medicine at UC San Diego Health, led a Phase III clinical trial investigating whether tocilizumab, a monoclonal antibody treatment for arthritis and other inflammatory diseases, might significantly improve the outcomes of patients with severe COVID-19 pneumonia.

It did not, Malhotra and colleagues reported in The New England Journal of Medicine, though they did observe a modest decrease in length of hospital stays and days on mechanical ventilators. Even when repurposed drugs do not achieve hoped-for results, Malhotra said, lessons are learned, which can guide new studies and help focus attention where it is most effective.